Effect of sevoflurane on the inflammatory response during cardiopulmonary bypass in cardiac surgery: the study protocol for a randomized controlled trial

[1] Passaroni AC(2015)Cardiopulmonary bypass: development of John Gibbon's heart-lung machine Braz J Cardiovasc Surg 30 235-245

[2] Silva MAM(2012)The volatile anesthetic sevoflurane inhibits activation of neutrophil granulocytes during simulated extracorporeal circulation Int J Immunopharmacol 14 202-208

[3] Yoshida WB(2014)Cardiospecific sevoflurane treatment quenches inflammation but does not attenuate myocardial cell damage markers: a proof-of-concept study in patients undergoing mitral valve repair Br J Anaesth 112 1005-1014

[4] Schmid E(2004)Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration Anesthesiology. 101 299-310

[5] Krajewski S(2013)Randomized trial on the effect of sevoflurane on polypropylene membrane oxygenator performance J Cardiothorac Vasc Anesth 27 903-907

[6] Bachmann D(2014)Use of volatile anesthetics during cardiopulmonary bypass: a systematic review of adverse events J Cardiothorac Vasc Anesth 28 84-89

[7] Kurz J(2013)Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study Anesthesiology. 98 1315-1327

[8] Wendel HP(2015)Identification of miRNAs involved in the protective effect of sevoflurane preconditioning against hypoxic injury in PC12 cells Cell Mol Neurobiol 35 1117-1125

[9] Rosenberger P(2011)The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ Nat Immunol 12 861-869

[10] Balkau B(2007)Prediction of microRNA targets Drug Discov Today 12 452-458

[1] Passaroni AC(2015)Cardiopulmonary bypass: development of John Gibbon's heart-lung machine Braz J Cardiovasc Surg 30 235-245

[2] Silva MAM(2012)The volatile anesthetic sevoflurane inhibits activation of neutrophil granulocytes during simulated extracorporeal circulation Int J Immunopharmacol 14 202-208

[3] Yoshida WB(2014)Cardiospecific sevoflurane treatment quenches inflammation but does not attenuate myocardial cell damage markers: a proof-of-concept study in patients undergoing mitral valve repair Br J Anaesth 112 1005-1014

[4] Schmid E(2004)Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration Anesthesiology. 101 299-310

[5] Krajewski S(2013)Randomized trial on the effect of sevoflurane on polypropylene membrane oxygenator performance J Cardiothorac Vasc Anesth 27 903-907

[6] Bachmann D(2014)Use of volatile anesthetics during cardiopulmonary bypass: a systematic review of adverse events J Cardiothorac Vasc Anesth 28 84-89

[7] Kurz J(2013)Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study Anesthesiology. 98 1315-1327

[8] Wendel HP(2015)Identification of miRNAs involved in the protective effect of sevoflurane preconditioning against hypoxic injury in PC12 cells Cell Mol Neurobiol 35 1117-1125

[9] Rosenberger P(2011)The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-γ Nat Immunol 12 861-869

[10] Balkau B(2007)Prediction of microRNA targets Drug Discov Today 12 452-458